SPL-IN-1

• UNSPSC Description:

  SPL-IN-1 (compound C17) is a dual species sphingosine-1-phosphate lyase inhibitor[1].

• Target Antigen:

  LPL Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/spl-in-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CCCOC(C1=C(SC2=C1CCCCC2)NC(CCCC(NC3=C(C4=C(S3)CCCCC4)C(OCCC)=O)=O)=O)=O

• Molecular Weight:

  602.80

• References & Citations:

  [1]Cellini B, et al. Dual species sphingosine-1-phosphate lyase inhibitors to combine antifungal and anti-inflammatory activities in cystic fibrosis: a feasibility study. Sci Rep. 2023;13(1):22692. Published 2023 Dec 20. |[2]Cellini B, et al. Dual species sphingosine-1-phosphate lyase inhibitors to combine antifungal and anti-inflammatory activities in cystic fibrosis: a feasibility study. Sci Rep. 2023;13(1):22692. Published 2023 Dec 20.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  353770-24-8